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Abstract 
Background: Sepsis is characterized by the loss of the perm-selectivity properties of the glomerular filtration barrier 
(GFB) with consequent albuminuria. We examined whether the pharmacokinetics–pharmacodynamics (PK/PD) of cef-
triaxone (CTX), an extensively protein-bound 3rd generation cephalosporin, is altered during early sepsis and whether 
an increase in urinary loss of bound-CTX, due to GFB alteration, can occur in this condition.
Methods: A prospective, experimental, randomized study was carried out in adult male Sprague–Dawley rats. 
Sepsis was induced by cecal ligation and puncture (CLP). Rats were divided into two groups: Sham-operated and 
CLP. CTX (100 mg i.p., equivalent to 1 g dose in humans) was administered in order to measure plasma and lung CTX 
concentrations at several time-points: baseline and 1, 2, 4 and 6 h after administration. CTX was measured by High 
Performance Liquid Chromatography (HPLC). The morphological status of the sialic components of the GFB barrier 
was assessed by lectin histo-chemistry. Monte Carlo simulation was performed to calculate the probability of target 
attainment (PTA >90%) for 80 and 100% of Tfree > minimum inhibitory concentration (MIC) for 80 and 100% of dosing 
interval.
Measurements and main results: After CLP, sepsis developed in rats as documented by the growth of polymi-
crobial flora in the peritoneal fluid (≤1 × 101 CFU in sham rats vs 5 × 104–1 × 105 CFU in CLP rats). CTX plasma 
concentrations were higher in CLP than in sham rats at 2 and 4 h after administration (difference at 2 h was 47.3, 
p = 0.012; difference at 4 h was 24.94, p = 0.004), while lung penetration tended to be lower. An increased urinary 
elimination of protein-bound CTX occurred (553 ± 689 vs 149 ± 128 mg/L, p < 0.05; % of bound/total CTX 22 ± 6 in 
septic rats vs 11 ± 4 in sham rats, p < 0.01) and it was associated with loss of the GFB sialic components. According to 
Monte Carlo simulation a PTA > 90% for 100% of the dosing interval was reached neither for sham nor CLP rats using 
MIC = 1 mg/L, the clinical breakpoint for Enterobacteriacee.
Conclusions: Sepsis causes changes in the PK of CTX and an alteration in the sialic components of the GFB, with 
consequent loss of protein-bound CTX. Among factors that can affect drug pharmacokinetics during the early phases 
of sepsis, urinary loss of both free and albumin–bound antimicrobials should be considered.
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Background
The effects of sepsis on the pharmacokinetics-pharma-
codynamics (PK/PD) of antimicrobials have been exten-
sively examined in recent years [1]. A major contribution 
to sepsis-induced changes in PK/PD is due to modifica-
tion in the volume of distribution (Vd) and renal clear-
ance. The latter [1–3] is frequently impaired and this fact 
may reduce drug elimination. However, in up to 20% of 
intensive care unit (ICU) patients, an increase in creati-
nine clearance (CrCL) occurs in the initial phases of sep-
sis and, as a consequence, an increase in drug elimination 
can ensue, with reduction in pathogen exposure to anti-
microbials [4]. Theoretically, the increase in CrCL should 
concern only the “free” antimicrobial, which is physiolog-
ically capable of crossing the glomerular filtration barrier 
(GFB), since the passage of ligand proteins such as albu-
min is normally prevented by the integrity of the GFB 
itself. A major contribution to the perm-selective proper-
ties of the GFB is provided by the glycocalyx, a network 
of glycoproteins, proteoglycans and soluble components 
which line the extracellular surface of all cells, including 
the glomerular endothelial cells and podocytes [5]. How-
ever it has been shown that sepsis impairs GFB proper-
ties, since albuminuria is an early marker of postoperative 
patients developing sepsis [6]. It is therefore likely that 
during sepsis even the quantity of antimicrobials bound 
to albumin is eliminated in the urine, which is consistent 
with the fact that the molecular weight of antimicrobials 
is usually negligible in comparison to albumin and other 
ligand proteins (<1000 vs 69,000  Da respectively) [7]. 
Among the antimicrobials indicated for treating abdomi-
nal or uro-sepsis in ICU patients, ceftriaxone (CTX), a 
highly protein-bound (>95%), third-generation cephalo-
sporin [8], maintains a role when susceptible pathogens 
are involved. For CTX, a time period during which free 
concentrations remains higher then MIC (Tfree  >  MIC) 
for at least 80% of the dosing interval is considered the 
optimal PK/PD target [9]. In critically ill patients, a fast 
(within 24–48  h) achievement of antimicrobial target 
concentrations is also of special importance in order to 
improve the outcome [1, 10].
Studies in ICU septic patients have shown very high 
variability in the main PK parameters of CTX, with 
changes in renal clearance representing the main cause 
[11]. No data is reported concerning increased elimina-
tion of CTX due to loss of GFB perm-selectivity.
In the present study, we have aimed therefore at eval-
uating in an experimental model of sepsis whether (1) 
changes in the PK of CTX occur from the beginning of 
sepsis, (2) whether these changes are associated with 
changes in the renal clearance of bound/unbound CTX 
and changes in the GFB perm-selectivity, (3) whether 
these changes have consequences on the probability of 
reaching the PK/PD target (calculated using Monte Carlo 
simulation).
Methods
Adult male Sprague–Dawley rats (Harlan, Udine, Italy) 
weighing 320–330 g were used for this study. The experi-
mental protocol was approved by the Committee for Ani-
mal Experimentation of the Ministry of Health, Rome, 
Italy. Animals were treated according to Italian and Euro-
pean Guidelines for Animal Care and Experimentation, 
DL 116/92, in agreement with the European Communi-
ties Council Directive guidelines (86/609/EEC).
The SD rats were initially housed three per cage in a 
temperature (18–22  °C) and humidity-controlled room 
under a constant 12-h light/dark cycle and fed with 
standard rat chow and water ad  libitum. After acclima-
tization, animals were identified from number 1–36 and 
then, by using the Microsoft Excel software (Lombar-
dia, Italy), assigned to one of the two study groups by a 
blind operator. Eighteen rats underwent sepsis (induced 
by cecal ligation and puncture (“CLP group”), and 18 
rats (who received laparotomy only) served as controls 
(“Sham-group”). At the end of the surgical procedure 
each rat received the same amount of CTX intra-perito-
neally (i.p.)(see below). A schematic representation of the 
experimental design is shown in Fig. 1.
The CLP procedure was performed as previously 
detailed [12–14]. Briefly, rats anesthetized with sodium 
pentobarbital (65  mg/kg, i.p.) and positioned on a 
homoeothermic heating pad in order to maintain body 
temperature between 36.5 and 37.5  °C, received a 3  cm 
midline laparotomy on the anterior abdomen. The 
cecum was exposed and ligated distally to the ileoce-
cal valve, without causing intestinal obstruction, and 
it was punctured on the anti-mesenteric border with a 
16  G (1.65  mm diameter) needle. The cecum was then 
squeezed to extrude its fecal content and was replaced 
into the peritoneal cavity; finally, a 20  G cannula was 
positioned in the peritoneal cavity and secured to the 
abdominal wall in order to subsequently inject CTX and/
or collect peritoneal samples. The anterior peritoneal wall 
and the skin were closed with 3-0 silk sutures. “Sham” 
animals underwent laparotomy and peritoneal cannula 
positioning only. After surgery, all the rats were housed 
individually for urine collection in metabolic cages in the 
same environmental conditions.
To document the development of sepsis, the clini-
cal appearance, mortality during the experimental time 
(6 h) and micro-organism growth in the peritoneal cavity 
were evaluated. For micro-organism detection and count, 
samples of peritoneal fluid were collected at the end of 
the experimental time (6 h) and cultured for the growth 
of Gram-positive and Gram-negative isolates. Samples 
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were incubated on Mannitol Salt Agar for 24 h at 37  °C 
for Gram-positive strains and layered on Mac-Conkey 
Agar III for 24  h at 37  °C for Gram-negative culture. 
Species identification was determined by the API sys-
tem (BioMerieux, Inc., Hazelwood, MO), using a panel 
Gram-positive (GP) card. The effects of sepsis on the sta-
tus of the GBF, and on CTX elimination were also exam-
ined (see below).
The CTX was purchased from Sigma-Aldricht Co. 
(Saint Louis, Missouri, USA). The antimicrobial solution 
was prepared daily by dissolving the powder in sterile 
saline. 100  mg/kg CTX was injected intra-peritoneally 
through the 20  G abdominal cannula in a volume of 
1 mL; the cannula was flushed immediately with 1 mL of 
saline. The dose of CTX was chosen according to previ-
ous experimental protocols in order to mimic the human 
dose of 1 g [15].
Plasma and lung concentrations were evaluated for the 
first 6 h after CTX administration. Serial blood samples 
(drawn from the tail vein) were collected at the following 
times: before the administration of the antibiotic (base-
line sample) and after 1, 2, 4 and 6 h (n =  at least four 
samples each experimental time). The blood was imme-
diately centrifuged at 4000 rpm for 15 min at 4 °C, plasma 
collected, divided into aliquots and stored at −80 °C until 
assayed. Lung specimens were also collected at 2, 4 and 
6 h after antibiotic treatments to evaluate antibiotic tis-
sue penetration into the lung. Finally, urinary samples 
were collected from the metabolic cage after the 6  h 
interval in order to measure CTX elimination.
The CTX concentrations were determined in tripli-
cate by a validated large-plate agar diffusion technique, 
according to Good Laboratory Practice (GPL) stand-
ards, using the Mueller–Hinton Agar (Oxoid, UK) as 
the culture medium and Escherichia coli K12 as the test 
organism, with a lower limit of sensitivity of 0.125 mg/L. 
Standard concentrations were prepared daily in pooled 
plasma for plasma samples, in saline for the urine and 
lung samples. The test organism (1 × 106 CFU/mL) was 
added using the surface layer technique. After homo-
geneous distribution of the culture, the excess liquid 
was removed with a pipette. The plates were incubated 
at 37  °C in air overnight. Best-fit standard curves were 
obtained by linear regression analysis. The correla-
tion coefficient was no less than 0.99. For all CTX sam-
ples, intra-assay precision ranged from 1.5 to 6.8% and 
the inter-assay precision at a level of 0.75  mg/L ranged 
from 4.6 to 5.6%. Amicon R 10 K filters (Sigma Aldrich, 
Milan Italy) were used for the determination of free drug 
concentration (the filter cut-off being 10.000 nominal 
Fig. 1 Experimental time course
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molecular weight limit). In short, 0.5  mL of plasma 
were stratified on the filters and centrifuged at 4000g for 
30 min. The filtrate was collected and analyzed with the 
same bioassay described above.
Diuresis was collected for each rat (at least four rats 
each group). The total amount of diuresis in the 0–6  h 
interval of time was noted. Urine was stored at −20  °C 
until examination.
Changes of GFB-associated glycocalyx, in particular 
in the sialic components, was performed by lectin histo-
chemistry. At the end of the experimental time, after the 
pentobarbital overdose, a midline incision was made in 
the abdomen, and kidney specimens were fixed in Car-
noy’s fluid and routinely processed to obtain 6 μm-thick 
paraffin sections. Maackia amurensis agglutinin (MAA) 
and Sambucus nigra agglutinin (SNA) digoxigenin (DIG) 
labeled lectins (Roche Diagnostic, Mannheim, Ger-
many) were used to identify sialic acids linked α2–3 and 
α2–6 to galactose or galactosamine, respectively. Lectin 
histo-chemistry was performed as previously described 
[16, 17]. In short, sections were treated with 20% ace-
tic acid to inhibit the endogenous alkaline phosphatase, 
then treated with 10% blocking reagent in Total Buffered 
Saline (TBS) to reduce the background labelling. After-
wards, sections were washed in TBS and rinsed in Buffer 
1, then incubated in DIG-labelled lectins diluted in Buffer 
1 (1 and 5 μL/mL for SNA and MAA respectively) for 1 h 
at room temperature. Sections were then rinsed in TBS, 
incubated with anti-digoxigenin, conjugated with alkaline 
phosphatase diluted in TBS and washed in TBS. Label-
ling of the sites containing bound lectin-digoxigenin was 
obtained by incubating slides with Buffer 2 containing 
nitroblue tetrazolium (NBT)/X-phosphate (Roche Diag-
nostics, Mannheim, Germany) [16, 18].
Controls for lectin specificity included pre-incubation 
of lectins with the corresponding hapten sugars [16, 18]. 
For evaluation of the lectin-stained location, ten ran-
dom fields (40× ocular) in each section (five sections for 
each specimen) were examined using light microscopy. 
A densitometric analysis was also carried out for lectin 
reactivity intensity by measuring the average optical den-
sity (OD) of region of interest (ROI, 40 µm2 area), using 
ImageJ National Institute of Health (NIH, Bethesda, 
MD, USA) software. Measured values were normalized 
to background [(OD-ODbkg)/ODbkg]. At least eight 
regions of interest in ten different optical fields were ana-
lyzed in each experiment.
For the PD analysis, the CTX concentration data on 
plasma were used to develop a population model by non- 
linear mixed effects modelling (using SAS 9.3 PROC 
NLMIXED).
We considered the following first-order compartment 
model for these
where Cit is the observed concentration of the i-th sub-
ject at time t, D is the dose of ceftriaxone, kei is the elimi-
nation rate constant for subject i, kai is the absorption 
rate constant for subject i, Cli is the clearance for subject 
i, and eit are normal errors. To allow for random variabil-
ity between subjects, we assumed:
where the βs denote fixed-effects parameters and the bis 
denote random-effects parameters with an unknown 
covariance matrix.
To obtain effect estimation and random effect joint dis-
tribution the matrix dual quasi-Newton algorithm was 
used in order to achieve convergence.
Two dosing regimens (100 and 200  mg/kg, cor-
responding to 1 and 2  g in humans respectively [15]) 
were simulated using Monte Carlo simulation based 
on the PK model. Each simulation generated con-
centration–time profiles from 10,000 rats per dosage 
regimen. Based on this data, Tfree > MIC and the proba-
bility target attainment (PTA) for different multiples of 
MIC, were estimated graphically. MIC values accord-
ing to the EUCAST breakpoints were considered, in 
which CTX susceptibility for Enterobacteriaceae was 
≤1 mg/L.
The free concentrations (Cfree) were estimated from the 
total concentrations (Ctot) using in  vivo binding param-
eters of CTX and the following equation described by 
Kodama et al. [19]:
The following binding of CTX was used: the total con-
centration of protein binding sites (nP) 517 μmol l−1 and 
the binding affinity constant (Kaff) 0.0367 l μmol−1.
In order to assess differences in continuous variables 
between the sham and CLP groups the t test or the 
Mann–Whitney test were used. The test choice was made 
following the Shapiro–Wilk test result for normality dis-
tribution of the variable in each group.
The difference between sham and CLP groups in PK 
parameters was assessed by Welch’s t-test. Statistical sig-
nificance was set at p value lower than 0.05.
Cit =
Dkeikai
Cli(kai − kei)
[
e−keit − e−kait
]
+ eit
Cli = e
β1+bi1
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Results
Sepsis was induced by CLP as documented by clinical 
signs (lethargy, pilo-erection, tachypnea) and growth of 
microorganisms in the peritoneal cavity. No spontane-
ous deaths occurred during the 6 h period. Both Gram-
positive and Gram-negative strains (Escherichia coli 70%, 
Enterococcus faecalis 40%, Streptococcus viridans 15%, 
and coagulase-negative Staphylococci 70%) were col-
lected at 6  h following surgery. Colony-forming units/
mm3 ranged from ≤1  ×  101 in sham-operated rats to 
5 × 104–1 × 105 in CLP rats.
The kinetic plasma profile of CTX in both groups is 
reported in Fig.  2. Peak plasma values were 132,48 and 
120,29 mg/L respectively in the CLP and sham-operated 
control groups. Plasma levels remained higher in septic 
than in sham-operated rats, with a statistical significance 
between the 2nd and 4th h (difference at 2 h 47.3 mg/L 
p = 0.012; difference at 4 h 24.94, p = 0.004). Clearance 
was significantly lower in CLP rats (0.21 vs 0.32  mL/
min p =  0.009). Despite the higher plasma levels, free/
unbound CTX penetration tended to be lower in lung 
tissue in septic rats than in controls (lung/plasma value 
being at 2 h, p = 0.2; at 4 h, p = 0.05; at 6 h, p = 0.6). (see 
Table 1) In septic rats, the calculated AUC lung/AUC free 
plasma concentration ratio was 0.33 while in the sham it 
was 0.51.
The concentration of bound CTX in the urine was sig-
nificantly higher in septic CLP-treated rats than in sham 
rats (553 ± 689 vs 149 ± 128 mg/L, p < 0.05; % of bound/
total CTX 22 ± 6 vs 11 ± 4, p < 0.01 respectively in CLP 
and sham rats). However the total amount of CTX elimi-
nated in the urine (calculated as urinary volume X CTX 
urinary concentration) was higher in sham than in CLP 
rats (3.34  ±  0.55 vs 1.85  ±  0.8  mg, p  <  0.05) because 
urinary volume in the time interval 0-6 h was higher in 
sham than in septic rats (2.25 ± 0.53 vs 1.24 ± 0.72 mL, 
p < 0.05). For details see Fig. 3a, b.
The integrity of the GFB-associated glycocalyx was 
assessed by lectin histo-chemistry analysis. MAA and 
SNA reactivity (showing the presence of sialic acids 
linked α-2,3 and α-2,6 to galactose/galactosamine, 
respectively) was significantly lower in the glomerular 
barrier in the CLP rats with respect to the sham-oper-
ated rats (MAA 0.38 ± 0.06 vs 0.97 ± 0.07, p < 0.01; SNA 
0.41 ± 0.05 vs 1.09 ± 0.09, p < 0.01, Fig. 4).
Monte Carlo simulation was performed to evaluate the 
PTA attainment of Tfree > MIC for over 80% and for 100% 
of the dosing interval.
The PTA for the 80% dosing interval was 0% for 
MIC = 1 mg/L with the 1 g dose, and 99% with the 2 g 
dose in the sham rats. In the CLP rats, the PTA for the 
80% dosing interval was 75% for MIC = 1 for the 1 g dose 
and 95% for the 2 g dose (Fig. 5a, b).
The PTA for the 100% dosing interval was 0% for 
MIC = 1 mg/L for both the 1 g and 2 g doses in both the 
sham rats (Fig. 5c) and the CLP rats (Fig. 5d).
Discussion
Our data show that the PK of CTX is modified from the 
very initial phases of sepsis in the sense that plasma con-
centrations are higher but lung penetration is generally 
lower compared to non-septic sham controls. Another 
important finding in our study is that, due to sepsis-
induced changes in GFB perm-selectivity, urinary loss of 
bound CTX is higher in septic than in sham rats. Finally, 
according to Monte Carlo simulation, despite the higher 
plasma levels of total CTX in septic rats, the dose admin-
istered which is equivalent to 1  g in humans is insuffi-
cient to reach a PTA >90% both for 80 and 100% of the 
dosing interval.
It is well known that optimal antimicrobial therapy is 
characterized by a PK/PD and time-targeted protocol in 
order to improve patients’ outcome. Therefore we have 
studied sepsis in its early phase to assess its effects con-
cerning the initial optimization of antimicrobial therapy. 
We have used the same model which we used in the 
past [12, 16] since it is suitable for the study of the first 
hours of sepsis because cytokine activation, microor-
ganism growth, impairment of the integrity of the sialic 
components of the GFB with consequent albuminuria 
Fig. 2 Total CTX plasma concentration (mg/L) time curve in septic 
(CLP, ●) and control (sham–operated, ×) rats (n = at least four rats 
each point)
Table 1 Free Ctx Lung Concentrations (mean  ±  SD) 
in sham and CLP rats
 Hours SHAM + CTX (mg/L) CLP + CTX (mg/L)
2 5.7 ± 0.6 5.0 ± 0.7
4 2.7 ± 1.2 2.6 ± 0.7
6 0.4 ± 1.7 1.0 ± 0.2
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have already occurred within this period of time [6, 18]. 
In the present study we have expanded our observations 
on early sepsis by examining whether modifications of 
highly-bound molecules like CTX were present and 
whether they were associated with increased renal loss of 
CTX.
We chose to study CTX because, although it is an “old” 
cephalosporin, it is commonly prescribed, being the sec-
ond most popular in acute care hospitals in the USA [20, 
21]. In some countries, it is also available in combination 
with the Beta-lactamases inhibitor Sulbactam and in this 
case it maintains a role for the treatment of ESBL-posi-
tive strains [22]. Moreover, it is interesting to evaluate the 
effects of sepsis and of increased GFB permeability on a 
drug which is extensively bound (>95%) and whose renal 
elimination occurs almost exclusively throughout glo-
merular filtration [23].
For all cephalosporins, the Tfree  >  MIC of the dosing 
interval is the PK/PD parameter which best predicts their 
efficacy, and the Tfree  >  MIC of 80–100% of the dosing 
interval for CTX has been considered the optimal target 
[9].
In a study on the PK-PD of CTX in 54 critically ill septic 
patients [24], the CTX PK parameters were extremely vari-
able: half–life ranged between 0.8 and 28 h, and the clear-
ance from 4 to 33  mL/min (=0.26–1.98  L/h), due to the 
different types of patients and/or organ failure. Despite this 
variability and no stratification, the authors conclude that 
with a 2 g dose CTX plasma levels are sufficient to exert 
maximal antimicrobial activity against all the most com-
mon susceptible abdominal pathogens. Garot et al. [8] who 
performed a Monte Carlo simulation on similar patients, 
showed that even with a 1 g dose a PTA >90 of 100% of 
the dosing interval can be achieved for MICs ≤1 mg/L and 
for Cl ≤120 mL/min. On the contrary, on the basis of our 
Monte Carlo simulation in our experimental model, even 
with the 2 g dose the optimal PK/PD target could not be 
guaranteed in the early phases of sepsis.
Acute Kidney Injury (AKI) is frequently observed in 
ICU patients but in the early phases of sepsis an increase 
in creatinine clearance has been described as well. A GFR 
above 130  mL/1.73  m2 has been found to be associated 
with sub-therapeutic trough concentrations of beta-lac-
tams [25]. However, so far the permeability properties 
of the GFB has not received attention [18]. Permeability 
of the glomerulus is indeed a highly specialized function 
which limits the passage of proteins and larger mole-
cules but allows water and small molecules to cross. This 
“perm-selectivity” is guaranteed only when the structural 
and ultra-structural integrity of the GFB is maintained, 
including that of its endothelium-associated glycocalyx, 
which is composed of membrane-bound glycoproteins 
and proteoglycans [26, 27].
In our experimental conditions, we have found that the 
loss of the sialic component of glycocalyx was associated 
with higher CTX-bound urinary loss in septic rats, thus 
supporting the hypothesis of a loss of perm-selectivity 
(16).
Antibiotic penetration into the lung is critical in order 
to obtain good clinical outcomes in ICU patients with 
pneumonia. Lung penetration of CTX should be theo-
retically similar to the percentage of the quantity of free 
drug and it should have been higher for septic rats than 
for controls. However, tissue penetration of betalac-
tams depends not only on linear plasma concentrations 
[28] but also on other factors, such as their physico-
chemical properties, changes in membrane permeability, 
re-arrangement of pulmonary circulation [29] and the 
tissue alteration due to the action of free-radical oxygen 
Fig. 3 a CTX urinary concentration (mg/L) at the end of the 
experimental time (6 h). A significant increased quantity of bound-
CTX was present in the urine of septic rats (553.53 vs 149.27 mg/L; 
*p < 0.05 CLP vs SHAM). b Total urinary loss of CTX (mg) at the end 
of the experimental time (6 h); the quantity was the product of the 
6 h urinary volume and CTX concentration. Due to a reduced urinary 
output, CTX total loss was reduced in septic rats (1.85 vs 3.34 mg 
*p < 0.05)
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production [30]. Therefore, not surprisingly, we observed 
reduced penetration in septic than in control lungs, in 
accordance with other studies [29, 31]. The higher plasma 
levels we found in septic rats may have several causes, 
such as higher intestinal absorption due to intestinal 
inflammatory vaso-dilation and reduced penetration into 
peripheral tissues. Finally, total CTX renal elimination 
depends not only on the CTX concentration but also on 
urinary volume and in our study septic rats produced less 
urine.
Limits of the study
This was a PK/PD study carried out on the rat, therefore 
its extrapolation to humans can only be hypothetical. 
However, the dose of 100 mg/kg we have used gives peak 
plasma levels similar to those observed in humans after 
1  g iv administration and the experimental time of 6  h 
may be equivalent to the 24 h interval in humans accord-
ing to trough values [15]. Significantly, the level of protein 
binding is similar in humans and rats [32], thus contrib-
uting to support the validity of our results: it underlines 
Fig. 4 Representative light microphotograph of Maackia amurensis agglutinin (MAA) (a, b) and Sambucus nigra agglutinin (SNA) (c, d) reactiv-
ity at 6 h in sham-operated and CLP-treated rats. Lectin reactivity is present in the glomerular barrier of both study groups; however, reactivity in 
glomerulus of CLP rats (b, d) appears weaker than in sham-operated ones (a, c). e The quantitative analysis for SNA and MAA content showed that 
MAA and SNA reactivity intensity is significantly lower in CLP compared to sham-operated samples (MAA: 0.28 vs 0.97; SNA 0.41 vs 1.09 *p < 0.01 
CLP vs SHAM). Scale bar = 25 mm. Data are the mean of OD values, at 6 h, both for sham-operated and CLP rats
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therefore the importance of taking into consideration the 
loss of bound antimicrobials through urine during sep-
sis. Other limitations of our study are: (1) the fact that we 
have measured CTX lung penetration in the homogenate 
of lung tissue and not in the Epithelial Lining Fluid; (2) 
we do not know if the administration of fluids would have 
increased urinary volume and thus the total loss of CTX. 
Finally, a 24  h circadian rhythm in CTX clearance has 
been shown which might contribute to daily CTX level 
variations; this is important especially for drugs adminis-
tered once a day [33]. However, all the experiments were 
conducted in the same time-frame (starting in the morn-
ing at 9 am).
Conclusions
A rapid attainment of therapeutic targets of antimicrobi-
als is a crucial element for an appropriate antimicrobial 
therapy in critically ill patients [10]. Our study confirms 
how sepsis impacts on the PK of CTX since the initial 
phase. Moreover it shows, for the first time, that among 
factors that can affect drug pharmacokinetics during the 
early phases of sepsis, urinary loss of both free and albu-
min-bound antimicrobials should be considered.
In view of the difficulty of predicting sepsis-associated 
changes in CTX PK, and in order to preserve the activ-
ity of this “old” antimicrobial and reduce the risk of 
resistance, the best way to adjust the dosage of CTX in 
Fig. 5 Monte Carlo simulation was performed to evaluate the PTA attainment of Tfree > MIC for over 80% and for 100% of the dosing interval. 
The PTA for the 80% dosing interval was 0% for MIC = 1 mg/L with the 1 g dose, and 99% with the 2 g dose in the sham rats. In the CLP rats, the 
PTA for the 80% dosing interval was 75% for MIC = 1 for the 1 g dose and 95% for the 2 g dose (a, b). Probability of target attainment (PTA) was 
calculated for the two dosing regimens 100 (blue line) and 200 (red line) mg/kg (corresponding to 1 and 2 g in humans respectively), using Monte 
Carlo simulation based on the PK model. The time period during which free concentrations remained higher then MIC (Tfree > MIC) and the PTA for 
different multiples of MIC were estimated graphically. MIC values according to the EUCAST breakpoints were considered, with CTX susceptibility for 
Enterobacteriaceae being ≤1 mg/L [34]. The PTA for the 100% dosing interval was 0% for MIC = 1 mg/L for both the 1 g and 2 g doses in both the 
sham rats (c) and the CLP rats (d)
Page 9 of 10Selmi et al. J Transl Med  (2016) 14:316 
critically ill patients appears to be therapeutic drug moni-
toring. Further studies are necessary to confirm these 
results in humans.
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